NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
NR 565 Advanced Pharmacology Fundamentals
Week 1 Quiz - Latest 2026/2027 Update - Chamberlain
Foundational Pharmacology for the Advanced Practice Prescriber
Total Questions: 60 (multiple choice, single best answer)
Cognitive Mix: 30% Recall | 50% Application | 20% Analysis
Format: 75% scenario-based | 25% direct recall
Sections: 6 NR 565 Week 1 content domains
Time Allotted: 90 minutes (average ~90 sec per question)
Passing Standard: Chamberlain NR 565 Week 1 Quiz - 80% correct
Examination Instructions
1. Each question has four response options (A, B, C, D). Select the single best answer.
2. "Which factor MOST affects..." and "Which drug property determines..." questions require application of
pharmacokinetic (PK) and pharmacodynamic (PD) principles to prescribing decisions.
3. The Correct Answer and a Rationale are provided immediately beneath each question for self-study review.
4. Rationales include pharmacokinetic principles, pharmacodynamic mechanisms, legal/DEA requirements, and prescriber
safety considerations. Distractors reflect common foundational pharmacology pitfalls.
5. The bolded maroon accent line marks the correct option. All other options are plausible distractors reflecting typical
foundational pharmacology reasoning errors.
SECTION 1 | Foundations of Pharmacology and Prescriptive
Q1 - Q10
Authority
Q1. The 1938 Federal Food, Drug, and Cosmetic Act was enacted largely in response to which historical
event that highlighted the dangers of an unregulated pharmaceutical market?
A. The sulfanilamide elixir disaster (Massengill), in which diethylene glycol toxicity caused over 100
deaths, mostly children; the Act required drugs to be proven safe before marketing [CORRECT]
B. The thalidomide tragedy of the 1960s
C. The Vioxx (rofecoxib) market withdrawal
D. The Fen-Phen cardiac valvulopathy crisis
Correct Answer: A
Rationale: The 1938 Federal Food, Drug, and Cosmetic Act was driven by the 1937 sulfanilamide elixir disaster, in
which over 100 people (mostly children) died from diethylene glycol (antifreeze) used as the solvent. The Act required
that drugs be shown to be SAFE before marketing and gave the FDA authority to enforce this. The 1962
Kefauver-Harris Amendment (B) added the requirement for proof of EFFICACY, spurred by the thalidomide tragedy
(which caused phocomelia in newborns in Europe but was largely prevented in the US by Dr. Frances Kelsey's FDA
review). Vioxx (C) and Fen-Phen (D) are post-marketing withdrawals of the late 1990s/early 2000s.
NR 565 Week 1 Quiz - 60 Questions Page 1
,NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q2. A nurse practitioner is examining the FDA approval pathway for a new biologic. Which of the
following correctly identifies the 1962 Kefauver-Harris Amendment's primary contribution to modern
drug regulation?
A. It required drugs to be proven SAFE before marketing
B. It required drugs to be proven both SAFE and EFFECTIVE (efficacy) before marketing, and
required informed consent for clinical trial participants [CORRECT]
C. It established the Controlled Substances Act schedules
D. It created the Orphan Drug Act
Correct Answer: B
Rationale: The 1962 Kefauver-Harris Amendment was enacted in response to the thalidomide tragedy (which caused
severe birth defects in Europe). It added the requirement for proof of EFFICACY (in addition to safety from 1938),
required informed consent for clinical trial participants, established Good Manufacturing Practices (GMP), and gave
the FDA authority to regulate drug advertising. The 1938 Act required safety (A). The Controlled Substances Act was
1970 (C). The Orphan Drug Act was 1983 (D).
Q3. A drug receives FDA approval with a designation that allows for expedited review because it treats a
serious condition and demonstrates substantial improvement over available therapy. Which pathway is
this?
A. Orphan drug designation
B. Accelerated approval (21 CFR Part 314 Subpart H) - for serious/life-threatening illnesses where a
surrogate endpoint reasonably predicts clinical benefit [CORRECT]
C. Over-the-counter (OTC) monograph
D. Generic drug (ANDA) approval
Correct Answer: B
Rationale: Accelerated Approval (Subpart H, 21 CFR 314) allows drugs for serious/life-threatening illnesses to be
approved based on a surrogate endpoint (e.g., tumor shrinkage, viral load) that reasonably predicts clinical benefit. The
drug company must conduct post-marketing (Phase 4) studies to verify the clinical benefit. Other expedited pathways:
Fast Track (drugs for serious conditions with unmet need - rolling review), Breakthrough Therapy (substantial
improvement over available therapy - intensive FDA guidance), Priority Review (6-month review vs 10-month
standard). Orphan Drug designation (A) is for rare diseases (<200,000 US patients). OTC monograph (C) and generic
ANDA (D) are not for new drug approvals.
NR 565 Week 1 Quiz - 60 Questions Page 2
,NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q4. A pharmaceutical company seeks to develop a drug for a rare disease affecting fewer than 200,000
people in the United States. Which regulatory pathway provides incentives including 7-year market
exclusivity, tax credits, and FDA assistance?
A. Breakthrough Therapy designation
B. Orphan Drug Act designation (1983) - provides 7-year exclusivity, tax credits for clinical trials,
FDA assistance, and reduced user fees for drugs treating rare diseases [CORRECT]
C. Priority Review voucher
D. Generic drug approval
Correct Answer: B
Rationale: The Orphan Drug Act of 1983 was enacted to encourage development of drugs for rare diseases (defined as
those affecting <200,000 people in the US, or for which there is no reasonable expectation of recovering R&D; costs
from US sales). Incentives: 7-year market exclusivity (from approval date), 25% tax credit for clinical trial costs, FDA
assistance in study design, waived/reduced PDUFA user fees (with rare pediatric disease priority review vouchers).
Breakthrough Therapy (A) is for serious conditions with substantial improvement over existing therapy. Priority Review
(C) is for drugs that would be a significant improvement in safety/effectiveness.
Q5. The FDA replaced the long-standing pregnancy letter categories (A, B, C, D, X) with the Pregnancy
and Lactation Labeling Rule (PLLR) in 2015. Which statement correctly describes the PLLR?
A. PLLR uses numeric categories 1-5 to classify drug safety in pregnancy
B. PLLR replaced letter categories with narrative text in three subsections: Pregnancy (8.1),
Lactation (8.2), and Females and Males of Reproductive Potential (8.3); each provides risk summary,
clinical considerations, and supporting data [CORRECT]
C. PLLR applies only to OTC medications
D. PLLR eliminated pregnancy labeling requirements entirely
Correct Answer: B
Rationale: The Pregnancy and Lactation Labeling Rule (PLLR), effective June 30, 2015, replaced the A-B-C-D-X
letter categories (which were often misinterpreted as a grading system). PLLR provides narrative text in 3 subsections:
8.1 Pregnancy (includes labor and delivery), 8.2 Lactation (replaces "Nursing Mothers"), and 8.3 Females and Males of
Reproductive Potential (pregnancy testing, contraception, infertility). Each subsection includes: Risk Summary, Clinical
Considerations (maternal and fetal risk, dose adjustments), and Data (human and animal study evidence). The
narrative format requires the prescriber to weigh risks and benefits based on the actual data.
NR 565 Week 1 Quiz - 60 Questions Page 3
, NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q6. An advanced practice registered nurse (APRN) in a state with full practice authority is establishing a
new practice. Which of the following correctly describes the prescriptive authority of an APRN in a
full-practice state?
A. APRNs may only prescribe under physician supervision
B. APRNs have full prescriptive authority including the ability to prescribe Schedule II-V controlled
substances independent of physician collaboration, subject to state Board of Nursing regulations and
DEA registration [CORRECT]
C. APRNs may only prescribe non-controlled medications
D. APRNs may prescribe only after a physician has reviewed the chart
Correct Answer: B
Rationale: In states with full practice authority (currently ~27 states + DC), APRNs (NPs, CNSs, CNMs, CRNAs) may
evaluate, diagnose, and prescribe medications (including Schedule II-V controlled substances) without required
physician collaboration or supervision, regulated by the Board of Nursing. APRNs must obtain their own DEA
registration to prescribe controlled substances. Some states require a transition-to-practice period (e.g., a specified
number of hours or years of supervised practice before independent practice). Reduced practice (C) and restricted
practice (A, D) states require collaborative agreements with physicians for some or all aspects of practice.
Q7. A nurse practitioner is applying for DEA registration to prescribe controlled substances. Which
correctly identifies the format of a valid DEA number for an individual practitioner?
A. Any 9-digit number assigned by the state
B. Two letters (first letter indicates type - B for physician/DO/APRN/PA, M for mid-level
practitioner in some registrations, etc.) followed by 7 digits, with the 7th digit being a "check digit"
equal to the units digit of (sum of digits 1+3+5 + 2x sum of digits 2+4+6) [CORRECT]
C. A 12-digit alphanumeric code
D. A 5-digit state license number
Correct Answer: B
Rationale: A DEA registration number consists of 2 letters followed by 7 digits. The first letter identifies the type of
registrant: B (physician/DO/PA/APRN - hospital/clinic), M (Mid-Level Practitioner - includes NPs, CNSs, CNMs in
some states), C, E, F (other types). The second letter is typically the first letter of the registrant's last name (for
individuals). The 7 digits include a check digit (7th digit) used to validate the DEA number: the check digit equals the
units (last) digit of (the sum of the 1st, 3rd, and 5th digits + twice the sum of the 2nd, 4th, and 6th digits). This math
check is a common exam question.
NR 565 Week 1 Quiz - 60 Questions Page 4
NR 565 Advanced Pharmacology Fundamentals
Week 1 Quiz - Latest 2026/2027 Update - Chamberlain
Foundational Pharmacology for the Advanced Practice Prescriber
Total Questions: 60 (multiple choice, single best answer)
Cognitive Mix: 30% Recall | 50% Application | 20% Analysis
Format: 75% scenario-based | 25% direct recall
Sections: 6 NR 565 Week 1 content domains
Time Allotted: 90 minutes (average ~90 sec per question)
Passing Standard: Chamberlain NR 565 Week 1 Quiz - 80% correct
Examination Instructions
1. Each question has four response options (A, B, C, D). Select the single best answer.
2. "Which factor MOST affects..." and "Which drug property determines..." questions require application of
pharmacokinetic (PK) and pharmacodynamic (PD) principles to prescribing decisions.
3. The Correct Answer and a Rationale are provided immediately beneath each question for self-study review.
4. Rationales include pharmacokinetic principles, pharmacodynamic mechanisms, legal/DEA requirements, and prescriber
safety considerations. Distractors reflect common foundational pharmacology pitfalls.
5. The bolded maroon accent line marks the correct option. All other options are plausible distractors reflecting typical
foundational pharmacology reasoning errors.
SECTION 1 | Foundations of Pharmacology and Prescriptive
Q1 - Q10
Authority
Q1. The 1938 Federal Food, Drug, and Cosmetic Act was enacted largely in response to which historical
event that highlighted the dangers of an unregulated pharmaceutical market?
A. The sulfanilamide elixir disaster (Massengill), in which diethylene glycol toxicity caused over 100
deaths, mostly children; the Act required drugs to be proven safe before marketing [CORRECT]
B. The thalidomide tragedy of the 1960s
C. The Vioxx (rofecoxib) market withdrawal
D. The Fen-Phen cardiac valvulopathy crisis
Correct Answer: A
Rationale: The 1938 Federal Food, Drug, and Cosmetic Act was driven by the 1937 sulfanilamide elixir disaster, in
which over 100 people (mostly children) died from diethylene glycol (antifreeze) used as the solvent. The Act required
that drugs be shown to be SAFE before marketing and gave the FDA authority to enforce this. The 1962
Kefauver-Harris Amendment (B) added the requirement for proof of EFFICACY, spurred by the thalidomide tragedy
(which caused phocomelia in newborns in Europe but was largely prevented in the US by Dr. Frances Kelsey's FDA
review). Vioxx (C) and Fen-Phen (D) are post-marketing withdrawals of the late 1990s/early 2000s.
NR 565 Week 1 Quiz - 60 Questions Page 1
,NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q2. A nurse practitioner is examining the FDA approval pathway for a new biologic. Which of the
following correctly identifies the 1962 Kefauver-Harris Amendment's primary contribution to modern
drug regulation?
A. It required drugs to be proven SAFE before marketing
B. It required drugs to be proven both SAFE and EFFECTIVE (efficacy) before marketing, and
required informed consent for clinical trial participants [CORRECT]
C. It established the Controlled Substances Act schedules
D. It created the Orphan Drug Act
Correct Answer: B
Rationale: The 1962 Kefauver-Harris Amendment was enacted in response to the thalidomide tragedy (which caused
severe birth defects in Europe). It added the requirement for proof of EFFICACY (in addition to safety from 1938),
required informed consent for clinical trial participants, established Good Manufacturing Practices (GMP), and gave
the FDA authority to regulate drug advertising. The 1938 Act required safety (A). The Controlled Substances Act was
1970 (C). The Orphan Drug Act was 1983 (D).
Q3. A drug receives FDA approval with a designation that allows for expedited review because it treats a
serious condition and demonstrates substantial improvement over available therapy. Which pathway is
this?
A. Orphan drug designation
B. Accelerated approval (21 CFR Part 314 Subpart H) - for serious/life-threatening illnesses where a
surrogate endpoint reasonably predicts clinical benefit [CORRECT]
C. Over-the-counter (OTC) monograph
D. Generic drug (ANDA) approval
Correct Answer: B
Rationale: Accelerated Approval (Subpart H, 21 CFR 314) allows drugs for serious/life-threatening illnesses to be
approved based on a surrogate endpoint (e.g., tumor shrinkage, viral load) that reasonably predicts clinical benefit. The
drug company must conduct post-marketing (Phase 4) studies to verify the clinical benefit. Other expedited pathways:
Fast Track (drugs for serious conditions with unmet need - rolling review), Breakthrough Therapy (substantial
improvement over available therapy - intensive FDA guidance), Priority Review (6-month review vs 10-month
standard). Orphan Drug designation (A) is for rare diseases (<200,000 US patients). OTC monograph (C) and generic
ANDA (D) are not for new drug approvals.
NR 565 Week 1 Quiz - 60 Questions Page 2
,NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q4. A pharmaceutical company seeks to develop a drug for a rare disease affecting fewer than 200,000
people in the United States. Which regulatory pathway provides incentives including 7-year market
exclusivity, tax credits, and FDA assistance?
A. Breakthrough Therapy designation
B. Orphan Drug Act designation (1983) - provides 7-year exclusivity, tax credits for clinical trials,
FDA assistance, and reduced user fees for drugs treating rare diseases [CORRECT]
C. Priority Review voucher
D. Generic drug approval
Correct Answer: B
Rationale: The Orphan Drug Act of 1983 was enacted to encourage development of drugs for rare diseases (defined as
those affecting <200,000 people in the US, or for which there is no reasonable expectation of recovering R&D; costs
from US sales). Incentives: 7-year market exclusivity (from approval date), 25% tax credit for clinical trial costs, FDA
assistance in study design, waived/reduced PDUFA user fees (with rare pediatric disease priority review vouchers).
Breakthrough Therapy (A) is for serious conditions with substantial improvement over existing therapy. Priority Review
(C) is for drugs that would be a significant improvement in safety/effectiveness.
Q5. The FDA replaced the long-standing pregnancy letter categories (A, B, C, D, X) with the Pregnancy
and Lactation Labeling Rule (PLLR) in 2015. Which statement correctly describes the PLLR?
A. PLLR uses numeric categories 1-5 to classify drug safety in pregnancy
B. PLLR replaced letter categories with narrative text in three subsections: Pregnancy (8.1),
Lactation (8.2), and Females and Males of Reproductive Potential (8.3); each provides risk summary,
clinical considerations, and supporting data [CORRECT]
C. PLLR applies only to OTC medications
D. PLLR eliminated pregnancy labeling requirements entirely
Correct Answer: B
Rationale: The Pregnancy and Lactation Labeling Rule (PLLR), effective June 30, 2015, replaced the A-B-C-D-X
letter categories (which were often misinterpreted as a grading system). PLLR provides narrative text in 3 subsections:
8.1 Pregnancy (includes labor and delivery), 8.2 Lactation (replaces "Nursing Mothers"), and 8.3 Females and Males of
Reproductive Potential (pregnancy testing, contraception, infertility). Each subsection includes: Risk Summary, Clinical
Considerations (maternal and fetal risk, dose adjustments), and Data (human and animal study evidence). The
narrative format requires the prescriber to weigh risks and benefits based on the actual data.
NR 565 Week 1 Quiz - 60 Questions Page 3
, NR 565 | Advanced Pharmacology Fundamentals - Week 1 Quiz Chamberlain | 2026/2027
Q6. An advanced practice registered nurse (APRN) in a state with full practice authority is establishing a
new practice. Which of the following correctly describes the prescriptive authority of an APRN in a
full-practice state?
A. APRNs may only prescribe under physician supervision
B. APRNs have full prescriptive authority including the ability to prescribe Schedule II-V controlled
substances independent of physician collaboration, subject to state Board of Nursing regulations and
DEA registration [CORRECT]
C. APRNs may only prescribe non-controlled medications
D. APRNs may prescribe only after a physician has reviewed the chart
Correct Answer: B
Rationale: In states with full practice authority (currently ~27 states + DC), APRNs (NPs, CNSs, CNMs, CRNAs) may
evaluate, diagnose, and prescribe medications (including Schedule II-V controlled substances) without required
physician collaboration or supervision, regulated by the Board of Nursing. APRNs must obtain their own DEA
registration to prescribe controlled substances. Some states require a transition-to-practice period (e.g., a specified
number of hours or years of supervised practice before independent practice). Reduced practice (C) and restricted
practice (A, D) states require collaborative agreements with physicians for some or all aspects of practice.
Q7. A nurse practitioner is applying for DEA registration to prescribe controlled substances. Which
correctly identifies the format of a valid DEA number for an individual practitioner?
A. Any 9-digit number assigned by the state
B. Two letters (first letter indicates type - B for physician/DO/APRN/PA, M for mid-level
practitioner in some registrations, etc.) followed by 7 digits, with the 7th digit being a "check digit"
equal to the units digit of (sum of digits 1+3+5 + 2x sum of digits 2+4+6) [CORRECT]
C. A 12-digit alphanumeric code
D. A 5-digit state license number
Correct Answer: B
Rationale: A DEA registration number consists of 2 letters followed by 7 digits. The first letter identifies the type of
registrant: B (physician/DO/PA/APRN - hospital/clinic), M (Mid-Level Practitioner - includes NPs, CNSs, CNMs in
some states), C, E, F (other types). The second letter is typically the first letter of the registrant's last name (for
individuals). The 7 digits include a check digit (7th digit) used to validate the DEA number: the check digit equals the
units (last) digit of (the sum of the 1st, 3rd, and 5th digits + twice the sum of the 2nd, 4th, and 6th digits). This math
check is a common exam question.
NR 565 Week 1 Quiz - 60 Questions Page 4
